Public-Private Genome Debate Resurfaces

Smoldering differences between the Celera Genomics Group and the Human Genome Project erupted last month as three leaders of the international public consortium published an online article in the Proceedings of the National Academy of Sciences (PNAS)1 criticizing the results published last year by Celera.2 For the first time in scientific literature, Robert Waterston of Washington University, Eric Lander of the Whitehead Institute for Biomedical Research's Center for Genome Research, and John Su

Written byBrendan Maher
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Celera scientists published a commentary two weeks later saying that the simulations performed by Waterston and colleagues were flawed and based on false assumptions.4

Philip Green, Howard Hughes Medical Institute investigator and professor of genome sciences at the University of Washington, argues that Adams is backpedaling. "The explicit claim is in Celera's [2001] paper that they did an assembly by the whole genome approach. You can't allow false claims to persist in the literature." Green also published a commentary dispelling, among other things, the widely held notion that the competition Celera brought to the human genome project was a good thing, saying instead that it "has the downside of encouraging shortcuts that may compromise the ultimate result."5

While some sequencing-center heads maintain these criticisms, others have ducked the fray. Richard Gibbs, director of the Baylor College of Medicine genome-sequencing center has had the help of Celera in the effort to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies